|
Apr 10
|
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
|
|
Apr 9
|
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
|
|
Apr 8
|
What Makes Glaukos Corporation (GKOS) a Compelling Stock?
|
|
Jan 15
|
GKOS Stock Gains Following Positive Study Data on iDose Platform
|
|
Jan 14
|
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
|
|
Jan 4
|
Glaukos price target raised to $157 from $149 at BTIG
|
|
Dec 24
|
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
|
|
Dec 23
|
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
|
|
Dec 21
|
The three-year returns have been stellar for Glaukos (NYSE:GKOS) shareholders despite underlying losses increasing
|
|
Dec 19
|
Glaukos price target raised to $185 from $152 at Truist
|